Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 4/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23770322 | 0.86 | TTK (0.45) | KMT2A | |
| SCHEMBL23770320 | 0.84 | MAPT (0.47) | KMT2AHTTROCK1NAMPTMAPK1 | |
| SCHEMBL23770102 | 0.84 | RAB9A (0.47) | KMT2AEPHX1KDRHTTADORA3 | |
| SCHEMBL23770341 | 0.83 | MAPT (0.38) | KMT2AHTTROCK1NAMPT | |
| SCHEMBL23770128 | 0.83 | NAMPT (0.39) | HTTROCK1NAMPT | |
| SCHEMBL23770107 | 0.81 | NPC1 (0.44) | KMT2AHTTADORA3 | |
| SCHEMBL23770077 | 0.81 | ABCC1 (0.43) | ROCK2ROCK1NAMPT | |
| SCHEMBL23770104 | 0.80 | CHRM4 (0.41) | ROCK1 | |
| SCHEMBL31659148 | 0.80 | CHRM4 (0.41) | ROCK1 | |
| SCHEMBL23770089 | 0.80 | KMT2A (0.49) | KMT2AEPHX1KDRHTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708353-B2 | Inhibitors of prolyl-tRNA-synthetase | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708353-B2 | Inhibitors of prolyl-tRNA-synthetase | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| US-20210253558-A1 | Inhibitors of Prolyl-tRNA-Synthetase | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708353-B2 | Inhibitors of prolyl-tRNA-synthetase | GARS1, AARS1, NSUN3 | KMT2A 2505/4885EPHX1 3679/4885HPGD 1816/4885 |
| US-20210253558-A1 | Inhibitors of Prolyl-tRNA-Synthetase | GARS1, AARS1, TRMT1 | KMT2A 2345/4885EPHX1 4120/4885HPGD 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.